Infant PCV13 Immune Response Weakened By Receiving Vaccination During Peak Respiratory Viral Seasons, Study Suggests

Infectious Disease Advisor (2/28, Basilio) reported a study found that “a blunted immune response was observed among young infants who received their first dose of a pneumococcal 13-valent conjugate vaccine (PCV13) during peak respiratory viral seasons.” A further analysis “of patients in the PCV13 group” showed that geometric mean serotype-specific IgG concentrations (GMCs) “after receipt of a booster dose at 13 months of age were higher than those following completion of the 3-dose series, indicating a robust booster response.” According to researchers, “The current study provides a unique opportunity to demonstrate both the influence of seasonality and increased carrier load on the immune response of infants to PCVs.” The study was published in Clinical Infectious Diseases.